Daewoong Pharma

069620 · KOSPI · ₩069620 · 대웅제약

₩99,900▲ ₩800 (0.81%)End-of-day · Oct 28, 2026 · End-of-day prices.
Trade
Alert me

Valuation model · Discounted cash flow (DCF)

We use a 5-year discounted cash flow: the value of the cash the business is expected to produce, in today's money.

Fair value per share

₩120,747

vs the current price (₩99,900)

Enterprise value
₩1.6T
Equity value
₩1.4T
WACC
6.8%

Model estimate based on the assumptions shown. Not a price target and not a buy or sell signal. This is not financial advice.

Bear / Base / Bull

Bear
₩33,843
−66.1%
Base
₩120,747
+20.9%
Bull
₩279,851
+180.1%

Bear: revenue growth 3 points lower every year, EBIT margin 2 points lower, WACC 1 point higher. Bull: the opposite.

Assumptions

Sign in to change the assumptions and see the results update. Sign in

Cycle options

Margin path

Every year uses the cycle-average margin (9.7%).

Revenue growth

  • 7.1%

    How much sales grow that year, compared with the year before.

    Default: the last 3 years' revenue growth (7.1% a year, annual reports), fading to 3% by year 5.

  • 6%

    How much sales grow that year, compared with the year before.

    Default: the last 3 years' revenue growth (7.1% a year, annual reports), fading to 3% by year 5.

  • 5%

    How much sales grow that year, compared with the year before.

    Default: the last 3 years' revenue growth (7.1% a year, annual reports), fading to 3% by year 5.

  • 4%

    How much sales grow that year, compared with the year before.

    Default: the last 3 years' revenue growth (7.1% a year, annual reports), fading to 3% by year 5.

  • 3%

    How much sales grow that year, compared with the year before.

    Default: the last 3 years' revenue growth (7.1% a year, annual reports), fading to 3% by year 5.

Business

  • 9.7%

    Operating profit as a share of revenue.

    Default: through-the-cycle average of the last 12 months and the last 5 annual reports' operating margins.

  • 27.5%

    Share of operating profit paid as corporate tax.

    Default: Korea's top corporate tax rate (25%) plus 10% local income tax.

  • 2.1%

    The non-cash cost of wearing out equipment, added back to cash flow (% of revenue).

    Default: average of the last 3 annual reports (cash flow statements; equipment and intangibles).

  • 14.3%

    Money spent on factories, equipment, software and other long-term assets (% of revenue).

    Default: average of the last 3 annual reports (cash flow statements; equipment and intangibles).

  • 13.1%

    Stock and unpaid customer bills, less unpaid supplier bills, as a % of revenue. Each year's extra revenue ties up this much more cash.

    Default: working capital (current assets less cash and deposits, minus current liabilities other than borrowings) as a share of revenue, averaged over the last 3 years.

Discount rate

  • 2%

    How fast cash flows keep growing every year after year 5.

    Default: about Korea's long-run inflation plus real growth.

  • 4.08%

    Yield on Korea's 10-year government bond: the return with almost no risk.

    Default: Korea Treasury Bond 10-year yield on 2026-10-29.

  • 0.6

    How much the share moves when the market moves: 1 means just like the market.

    Default: 105 weeks of weekly returns against KOSPI (official index); raw beta 0.09, adjusted toward 1 and kept between 0.6 and 2.0.

  • 5.5%

    The extra return investors want for owning shares instead of bonds.

    Default: a typical premium for Korean shares.

  • 5.58%

    The interest rate the company would pay to borrow.

    Default: the 10-year yield plus a 1.5% credit spread.

Starting point

Revenue (TTM to H1 2026)
₩1.6T
Net debt (borrowings and leases − cash and deposits)
₩241B
+ Stakes and investments
₩135B
Associates, long-term financial assets and deposits (book value)
− Minority interests
₩128B
Shares
11,586,575
Share price
₩99,900
Market cap
₩1.2T

TTM = trailing 12 months: the last four reported quarters added together. "TTM to H1 2026" is the 12 months up to the latest quarterly or half-year report (H1 = to the end of June). Year 1 grows from there.

Past years and projection

Grey columns are reported results from the annual reports (after-tax EBIT at the model's tax rate), so you can check the growth and margin assumptions against the past. Years 1–5 are the model.

FY2023FY2024FY2025Year 1Year 2Year 3Year 4Year 5
Revenue₩1.4T₩1.4T₩1.6T₩1.8T₩1.9T₩1.9T₩2T₩2.1T
Growth7.4%3.4%10.4%7.1%6.0%5.0%4.0%3.0%
EBIT₩123B₩148B₩197B₩170B₩180B₩189B₩197B₩203B
EBIT margin8.9%10.4%12.5%9.7%9.7%9.7%9.7%9.7%
After-tax EBIT₩89B₩107B₩143B₩123B₩131B₩137B₩143B₩147B
+ Depreciation₩29B——₩37B₩39B₩41B₩43B₩44B
− Capital spending₩156B₩229B₩241B₩250B₩265B₩279B₩290B₩299B
− Working capital−₩37B₩46B₩59B₩15B₩14B₩12B₩10B₩8B
Free cash flow−₩1.6B——−₩106B−₩110B−₩113B−₩115B−₩116B
Discount factor———0.9360.8770.8210.7680.719
Present value———−₩99B−₩96B−₩93B−₩88B−₩83B

Terminal value ₩2.9T, worth ₩2.1T today: 128% of enterprise value. It assumes spending settles at 110% of depreciation once growth slows to the terminal rate.

Cross-check: what the market has paid before

For cyclical businesses, analysts check a DCF against the multiples the stock has traded at through past cycles. Price / book is the usual anchor for them: P/E looks highest at the bottom of a cycle, when earnings are smallest, and lowest at the top. The price each band would give today:

LowTypicalHigh
Price / book (book value ₩91,825 a share)Now 1.09×₩137,5411.50×₩183,2762.00×₩304,2103.31×
Price / earnings (last 12 months: ₩16,871 a share)Now 5.92×₩127,7327.57×₩369,82121.9×₩731,41943.4×
P/E on run-rate earnings (Q2 2026 × 4: ₩11,519 a share)Now 8.67×₩87,2147.57×₩252,50921.9×₩499,40343.4×

Low, typical and high are the 10th percentile, middle and 90th percentile of month-end multiples since 2021, each against the latest report out by then, per share at today's share count; loss years and P/E above 100 are left out. Run-rate earnings are one quarter × 4, not a forecast. Model estimate based on the assumptions shown. Not a price target and not a buy or sell signal.

Sensitivity

Fair value per share as two inputs change; the middle is the current case.

WACC ↓ · Terminal growth →1.0%1.5%2.0%2.5%3.0%
5.8%₩130,219₩151,356₩178,023₩212,727₩259,762
6.3%₩108,745₩125,415₩145,934₩171,821₩205,508
6.8%₩91,157₩104,566₩120,747₩140,666₩165,794
7.3%₩76,523₩87,489₩100,505₩116,212₩135,547
7.8%₩64,189₩73,281₩83,925₩96,560₩111,805

Now (TTM)

Market cap
₩1.2T
Enterprise value
₩1.4T
P/E
5.9×
P/B
1.1×
P/S
0.7×
EV/EBITDA
—
Dividend yield
0.6%

Over time (at each year end)

20252024202320222021
Price₩172,300₩126,400₩116,800₩158,500₩148,000
Market cap₩2T₩1.5T₩1.4T₩1.8T₩1.7T
P/E10.2×59.2×11.1×43.5×69.5×
P/B2.0×1.8×1.8×3.0×3.0×
P/S1.3×1.0×1.0×1.4×1.5×
EV/EBITDA——10.9×17.3×17.6×
Dividend yield0.3%0.5%———

Versus similar companies

CompanyP/EP/BP/SEV/EBITDADividend yield
Daewoong Pharma5.9×1.1×0.7×—0.6%
Samsung Biologics32.0×7.6×14.0×—0.0%
Celltrion27.9×2.5×9.0×—0.0%
Alteogen80.5×29.0×61.2×—0.1%
SK biopharmaceuticals14.7×5.8×6.8×—0.0%
Yuhan24.0×2.4×2.5×31.3×0.8%
HLB—15.7×55.6×—0.0%
Similar companies (median)27.9×6.7×11.5×31.3×0.0%

Calculated from end-of-day prices and filed financial statements. Not a recommendation. This is not financial advice.

Also known as: Daewoong Pharma / 대웅제약 / 069620 / KRX:069620

Source: KRX statistical information